Browsing Tag
Roche Holding AG
11 posts
Roche’s Columvi shows durable three-year overall survival edge over Rituxan in phase III STARGLO trial
Find out how Roche’s Columvi delivered a durable three-year survival advantage in the phase III STARGLO lymphoma trial and what it means for patients and investors.
December 8, 2025
Roche secures FDA clearance and CE Mark for rapid pertussis point-of-care diagnostic test
Discover how Roche’s FDA-cleared rapid pertussis test could transform point-of-care diagnosis and reshape decentralized molecular diagnostics worldwide.
December 2, 2025
Can Roche’s 62% success rate in breast cancer trials spark the next oncology breakthrough?
Roche’s new oral breast-cancer therapy cut disease-progression risk by up to 62% in late-stage trials. Find out how it could reshape treatment in 2025.
October 18, 2025
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
September 23, 2025
89bio stock soars 85% as Roche seals $3.5bn takeover—What’s behind the surge and what’s next?
Roche is buying 89bio for up to $3.5B to add Phase 3 MASH drug pegozafermin. Find out what the CVR means and how investors should read the deal today.
September 19, 2025
Eisai’s etalanetug earns FDA Fast Track status, signaling new hope in Alzheimer’s therapy
Eisai’s etalanetug gets FDA Fast Track for Alzheimer’s, signaling a major shift toward tau-targeting therapies. Find out what this means for investors.
September 17, 2025
Why Henlius Biotech’s HLX43 deal talks with Johnson & Johnson and Roche are shaking up global oncology
Henlius Biotech is negotiating with Johnson & Johnson and Roche on HLX43 rights. Learn how this deal could reshape oncology licensing and investor sentiment.
September 16, 2025
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
June 4, 2025
Atezolizumab slashes colon cancer recurrence by 50% in ATOMIC trial: ASCO 2025 breakthrough
Genentech’s Tecentriq cuts recurrence risk by 50% in dMMR colon cancer, setting the stage for new adjuvant approvals after ATOMIC trial success.
June 3, 2025
MicroAlgo crashes 20%, Trump Media slips again—here’s why markets panicked
Explore why 25 top U.S.-listed stocks tumbled on April 2 as Trump’s tariff strategy ignited fears of inflation, recession, and global retaliation.
April 3, 2025